Get the Stockscreener App
0.6962
5.33%
0.0352
Prelude Therapeutics Inc stock is traded at $0.6962, with a volume of 259.05K.
It is up +5.33% in the last 24 hours and down -23.16% over the past month.
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.
See More
Previous Close:
$0.661
Open:
$0.7121
24h Volume:
259.05K
Relative Volume:
0.68
Market Cap:
$38.32M
Revenue:
-
Net Income/Loss:
$-131.52M
P/E Ratio:
-0.3911
EPS:
-1.78
Net Cash Flow:
$-107.56M
1W Performance:
-7.79%
1M Performance:
-23.16%
6M Performance:
-85.59%
1Y Performance:
-83.02%
1-Day Range:
$0.69
$0.7579
1-Week Range:
$0.66
$0.86
52-Week Range:
$0.66
$6.80
Prelude Therapeutics Inc Stock (PRLD) Company Profile
Name
Prelude Therapeutics Inc
Sector
Industry
Phone
(302) 467-1280
Address
175 INNOVATION BOULEVARD, WILMINGTON
Compare PRLD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRLD
Prelude Therapeutics Inc
|
0.6962 | 38.32M | 0 | -131.52M | -107.56M | -1.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
495.42 | 127.22B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
689.50 | 75.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.45 | 35.94B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.43 | 31.38B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.84 | 26.84B | 3.32B | -860.46M | -1.04B | -8.32 |
Prelude Therapeutics Inc Stock (PRLD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-19-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-20-24 | Downgrade | Barclays | Equal Weight → Underweight |
| Mar-13-24 | Initiated | JMP Securities | Mkt Outperform |
| Feb-20-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-19-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Nov-21-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-29-22 | Initiated | Jefferies | Buy |
| Mar-15-22 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-28-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Oct-08-21 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-27-21 | Upgrade | BofA Securities | Neutral → Buy |
| Apr-26-21 | Initiated | H.C. Wainwright | Buy |
| Mar-09-21 | Initiated | Barclays | Overweight |
| Nov-20-20 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-20-20 | Initiated | BofA Securities | Buy |
| Oct-20-20 | Initiated | Goldman | Neutral |
| Oct-20-20 | Initiated | Morgan Stanley | Equal-Weight |
View All
Prelude Therapeutics Inc Stock (PRLD) Latest News
Prelude Therapeutics Reports 2024 Financial Results - TipRanks
Prelude Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Prelude Therapeutics reports FY24 EPS ($1.68), consensus ($1.77) - TipRanks
Prelude Therapeutics Reports 2024 Financial Results and Updates - TipRanks
Prelude Therapeutics Inc SEC 10-K Report - TradingView
Prelude Therapeutics Reports Full Year 2024 Financial Results and Provides Program Outlook for 2025 - GlobeNewswire
Prelude Therapeutics to Present at Barclays Global Healthcare Conference - MSN
Aclaris Therapeutics to Participate in Upcoming Healthcare Conferences - MyChesCo
Prelude Therapeutics to Participate in Barclays 27th Annual Global Healthcare Conference - GlobeNewswire
How Will Prelude's Cancer Pipeline Updates Impact Investors at Upcoming Barclays Conference? - StockTitan
Larimar Therapeutics to Present at Leerink Partners Global Healthcare Conference - MyChesCo
We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully - Yahoo Finance
Prelude Therapeutics Shares Promising Data for CDK9 Inhibitor PRT2527 - MSN
Prelude Therapeutics (PRLD) Stock Price, News & Analysis - MarketBeat
Prelude Therapeutics (PRLD) to Release Quarterly Earnings on Thursday - Defense World
Delaware weekly roundup: The Eagles’ River; CAFE opens apps; Prelude Therapeutics hires CFO - Technical.ly
Akoya Biosciences Inc (AKYA)’s Day in Review: Closing at 2.34, Down by -4.88 - The Dwinnex
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Prelude Therapeutics Names Bryant Lim As Permanent CFO -February 05, 2025 at 06:35 pm EST - Marketscreener.com
Prelude Therapeutics Appoints Bryant D. Lim as CFO - TipRanks
Prelude Therapeutics Reports Q3 2024 Results and Clinical Progress - MSN
Prelude Therapeutics Releases Promising Phase 1 Data on Novel Cancer Treatment - MSN
D2 Capital Advisors secures $23.5m for Residence Inn in Wilmington - Hotel Management Network
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares Purchased by Barclays PLC - Defense World
Adenoid Cystic Carcinoma Market reached US$ 224.3 million - openPR
US Penny Stocks To Watch In January 2025 - Simply Wall St
A Look At The Behavior Of Prelude Therapeutics Inc (PRLD) Stock - Stocks Register
Geode Capital Management LLC Grows Stake in Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World
Prelude Therapeutics Incorporated (NASDAQ:PRLD) Stake Lifted by Barclays PLC - Defense World
State Street Corp Raises Stock Position in Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World
Prelude Therapeutics CEO Vaddi Krishna buys $6,043 in common stock - Investing.com India
Prelude Therapeutics CEO Vaddi Krishna buys $6,043 in common stock By Investing.com - Investing.com UK
Prelude Therapeutics CEO Vaddi Krishna acquires $12,000 in stock - Investing.com
Prelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Krishna Vaddi Acquires 10,000 Shares - MarketBeat
Insider Buying: Andrew Combs Acquires 63,075 Shares of Prelude T - GuruFocus.com
Andrew Combs Purchases 60,000 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD) Stock - MarketBeat
XTX Topco Ltd Makes New $100,000 Investment in Prelude Therapeutics Incorporated (NASDAQ:PRLD) - Defense World
Krishna Vaddi Bought 4.9% More Shares In Prelude Therapeutics - Yahoo Finance UK
Insider Buying: Prelude Therapeutics Incorporated (NASDAQ:PRLD) CEO Purchases 100,000 Shares of Stock - MarketBeat
Prelude Therapeutics Incorporated (NASDAQ:PRLD) CFO Purchases $22,750.00 in Stock - MarketBeat
Prelude Therapeutics CEO Krishna Vaddi buys $99,325 in stock By Investing.com - Investing.com South Africa
Prelude Therapeutics’ interim CFO Bryant Lim buys $22,637 in stock By Investing.com - Investing.com Nigeria
Prelude Therapeutics' interim CFO Bryant Lim buys $22,637 in stock - Investing.com India
Prelude Therapeutics CEO Krishna Vaddi buys $99,325 in stock - Investing.com
Larimar Therapeutics Reports Promising Results for Friedreich’s Ataxia Treatment - MyChesCo
What Did We Find About Insider Trading At Prelude Therapeutics Inc (NASDAQ: PRLD)? - Stocks Register
Prelude Therapeutics' SWOT analysis: biotech stock faces pivotal year ahead By Investing.com - Investing.com Canada
Palvella Therapeutics and Pieris Pharmaceuticals Finalize Merger to Focus on Rare Disease Treatments - MyChesCo
PRLD Stock Touches 52-Week Low at $0.91 Amid Market Challenges - Investing.com Canada
Aprea Therapeutics Updates ABOYA-119 Trial with Twice Daily Dosing - MyChesCo
Windtree Therapeutics Files Patent for Istaroxime Derivatives to Combat Acute Myocardial Arrhythmia - MyChesCo
Prelude Therapeutics Inc Stock (PRLD) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.70%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):